Marex Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Marex Group’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,400	Closed	-$226K	–	907
2025 Q1	$226K	Hold	4,400	–	–	﹤0.01%	551
2024 Q4	$244K	Buy	+4,400	New	+$200K	﹤0.01%	491

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Marex Group's TARS Position: Q2 2025 in Review

Marex Group sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 4,400 shares — an estimated $226K sold.

Marex Group first reported a position in TARS in Q4 2024 and held it in 2 quarters. The position peaked at $244K in Q4 2024. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

Marex Group reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Marex Group sold 4,400 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $226K.
Marex Group first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Marex Group's Tarsus Pharmaceuticals position peaked at $244K in Q4 2024.
205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on Marex Group's 13F filing for Q2 2025, filed 19 Aug 2025.